Allergy & Hypersensitivity
Allergy & Hypersensitivity
At ImmunitasBio, we help you develop novel anti-allergic therapeutics and evaluate the immunotoxicity of new drug candidates with precise, functional models. We use specialized preclinical assays to study both IgE-mediated immediate hypersensitivity and T-cell-mediated delayed-type hypersensitivity, helping you bridge the translational gap from early discovery to IND-enabling studies
Type I Hypersensitivity: IgE-Mediated Responses:
When we model immediate allergic reactions, we focus on robust functional cellular assays that measure basophil and mast cell activation.
Basophil Activation Test (BAT):
A high-sensitivity flow cytometry assay quantifying the upregulation of CD63 and CD203c to evaluate basophil activation following drug or allergen stimulation.
Mast Cell Degranulation:
Functional assays utilizing mature mast cells sensitized with IgE to measure antigen-driven activation and morphological degranulation.
Mediator Release Profiling:
Precise quantification of pre-formed mediators (histamine) and newly synthesized cytokines (IL-4, IL-3) or lipid metabolites (LTC4) via ELISA, fluorometry, or spectrophotometry.
Type IV Hypersensitivity: Sensitization Models
To assess skin sensitization and drug-induced delayed hypersensitivity, we use predictive in vitro models that evaluate dendritic cell maturation and T-cell activation.
T-Cell Priming Assay (TCPA):
Single-cell evaluation of chemical-specific naive human T-cells, measuring proliferation and IFN-γ production.
Myeloid U937 Skin Sensitization Test (MUSST):
An in vitro dendritic cell activation model utilizing the U937 cell line to measure CD86 induction via flow cytometry.
Human Cell Line Activation Test (h-CLAT):
Flow cytometry-based quantification of CD86 and CD54 surface markers on THP-1 cells to effectively discriminate sensitizing drug candidates.
